Subscribe to Entrepreneur for $5

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher Scientific, Salesforce, Nike and Texas Instruments

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher Scientific, Salesforce, Nike and Texas Instruments

This story originally appeared on Zacks

For Immediate Release

Chicago, IL – December 20, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Thermo Fisher Scientific Inc. TMO,, inc. CRM, NIKE, Inc. NKE and Texas Instruments Inc. TXN.

- Zacks

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Berkshire Hathaway, Thermo Fisher and salesforce

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway, Thermo Fisher Scientific, and These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Berkshire Hathaway have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+31% vs. +16.6%). The Zacks analyst believes that Berkshire Hathaway is poised to benefit from its insurance, manufacturing, service and retail businesses, and disciplined capital management.

A strong cash position supports earnings-accretive bolt-on buyouts, and indicates BRK.B’s financial flexibility. Continued insurance business growth fuels increase in the float, drive earnings and generates maximum return on equity. A sturdy capital level provides further impetus. Exposure to catastrophe loss, however, leads to earnings volatility and also impacts the property and casualty underwriting results of Berkshire.

(You can read the full research report on Berkshire Hathaway here >>>)

Thermo Fisher shares have gained +39.8% in the year to date period against the Zacks Medical Instruments industry’s gain of +7%. The Zacks analyst sees that Thermo Fisher has been expanding its inorganic growth profile through takeovers such as the Advanced Bioprocessing buyout from BD and Patheon.

TMO’s focus on emerging markets is also encouraging. Thermo Fisher delivered a strong performance in the last-reported third quarter, leveraging on a significant rebound in its base business. Strong end-market growth in the quarter was driven by robust fundamentals in life sciences, strong economic activity globally and a strong pandemic response. TMO’s raised 2021 guidance indicates that the momentum is likely to continue through the next year.

(You can read the full research report on Thermo Fisher here >>>)

Shares of have gained +2.4% in the last six months against the Zacks Computer Software industry’s gain of +19.3%, but things seem to be improving. The Zacks analyst believes that CRM has been benefiting from a robust demand environment as customers are undergoing a major digital transformation.

The rapid adoption of its cloud-based solutions is driving demand for its products. The recent acquisition of Slack is likely to position salesforce as a leader in enterprise team collaboration solution space. Stiff competition, unfavorable currency fluctuations, and increasing investments in international expansion are some of the major headwinds, though.

(You can read the full research report on here >>>)

Other noteworthy reports we are featuring today include Nike and Texas Instruments.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


Texas Instruments Incorporated (TXN): Free Stock Analysis Report, inc. (CRM): Free Stock Analysis Report


NIKE, Inc. (NKE): Free Stock Analysis Report


Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report


Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report


To read this article on click here.


Zacks Investment Research